Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Provider Statement
This continuing medical education activity is provided by 
.
Support Statement
This activity is supported by educational grants from Takeda Pharmaceuticals U.S.A., Inc. and Novo Nordisk, Inc.
Target Audience
The intended audience for this activity is endocrinologists, internal medicine physicians, bariatric and obesity specialists, and other health care professionals involved in the treatment of patients with obesity.
Learning Objectives
Upon successful completion of this educational activity, participants should be better able to:
- Implement obesity counseling for eligible patients using evidence-based communication frameworks, such as motivational interviewing and the 5As.
- Evaluate current data on the safety and efficacy of currently available medications for the treatment of overweight and obesity.
- Identify patients with obesity who would benefit from pharmacotherapy and select therapy based upon individual patient needs and preferences.
Activity Chair:
Robert F. Kushner, MD, MS, FACP, FTOS
Professor of Medicine
Northwestern University
Feinberg School of Medicine
Chicago, IL
Faculty:
Ken Fujioka, MD, FTOS
Director, Nutrition and Metabolic Research
Division of Diabetes and Endocrinology
Scripps Clinic
San Diego, CA
Scott Kahan, MD, MPH, FTOS
Director, National Center for Weight and Wellness
Medical Director, Strategies to Overcome and Prevent (STOP) Obesity Alliance
George Washington University
Milken Institute School of Public Health
Washington, DC
Reviewers
Ronald Codario, Jr., MD
Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP (Recertification review on 12/8/2017 and 12/8/2018)
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material was originally approved for 1 year from the date of original release, December 18, 2015, to December 17, 2016. It has since been recertified for 3 additional years and will now expire on December 8, 2019.
How To Participate in this Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives, answer the pretest question, review the CME content, complete the CME posttest, and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page.
Activity Chair and Faculty report the following relationship(s) which are accurate at the time of original content release (December 18, 2015):
Robert F. Kushner, MD, MS, FACP, FTOS
Consulting Fee: Novo Nordisk, Inc., Retrofit, Takeda Pharmaceuticals, Weight Watchers, Zafgen
Contracted Research: Aspire Bariatrics, Weight Watchers
Ken Fujioka, MD, FTOS
Consulting Fee: Eisai, Inc., Enteromedics, Isis Pharmaceuticals, Inc., Nazura, Novo Nordisk, Inc., Takeda Pharmaceuticals, Zafgan
Speakers Bureau: Eisai, Inc., NPS, Takeda Pharmaceuticals
Contracted Research: Eisai, Inc., Enteromedics, Novo Nordisk, Inc., Orexigen, Shire, Weight Watchers
Scott Kahan, MD, MPH, FTOS
Advisory boards/consulting/research: Eisai, Inc., Novo Nordisk, Inc., Takeda Pharmaceuticals, Vivus, Inc.
Speakers Bureau: Eisai, Inc., Novo Nordisk, Inc., Takeda Pharmaceuticals, Vivus, Inc.
Board of Directors: American Board of Obesity Medicine
Book royalties: Johns Hopkins University Press, Lippincott Williams & Wilkins, Wolters Kluwer
Reviewers report the following relationship(s):
Ronald Codario, Jr., MD
No relevant financial relationships to disclose.
Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2015 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com